TAIPEI, TAIWAN – As the finalized U.S.-Taiwan reciprocal tax agreement ushers in a new era of “Globalization 4.0,” Taiwanese precision diagnostics innovator MarkerX (銳準生醫) has achieved a major international milestone. The company’s flagship product, “MyeloTrak, a breakthrough solution for monitoring Multiple Myeloma relapse, has been selected for the 2026 Mayo Clinic and ASU Alliance for Health Care Accelerator.
Co-led by Mayo Clinic in Arizona and Arizona State University, this highly competitive program identifies high-potential medical technology startups to fast-track their commercialization. Marker X’s selection serves as a powerful validation of its R&D prowess in precision medicine and marks a pivotal moment for Taiwan’s biotechnology sector on the global stage.
Mayo Clinic: A Global Leader in Specialized Care
Mayo Clinic has been ranked the #1 hospital in the world for six consecutive years by Newsweek and Statista. Renowned for its clinical excellence, Mayo Clinic is a global authority in Multiple Myeloma (MM)—a blood cancer arising from plasma cells in the bone marrow. MM is the second most common blood cancer worldwide, with approximately 36,000 new cases diagnosed annually in North America alone. By leveraging Mayo Clinic’s vast clinical datasets and world-class expertise, the accelerator program aims to scale transformative solutions that improve global patient outcomes.
MarkerX: Advancing Blood-Based Monitoring for Cancer Care
Marker X focuses on developing next-generation biomarker technologies that enable earlier detection of disease changes through proteomic analysis. The company previously gained recognition for its AI-driven multi-cancer early detection research and is now drawing attention with its technology for monitoring relapse in multiple myeloma, which has been selected by the Mayo Clinic and Arizona State University Health Care Accelerator program.
Marker X’s MyeloTrak is a blood-based assay designed for monitoring multiple myeloma, offering sensitivity approaching that of bone-marrow–based testing while requiring only a routine blood draw. By reducing the need for frequent bone marrow procedures, the test has the potential to make disease monitoring more accessible and less burdensome for patients, while enabling physicians to detect signs of relapse earlier and make timely treatment decisions.
Through advanced proteomic analysis and proprietary algorithms, MyeloTrak can identify and track disease-related signals unique to each patient, improving monitoring precision while minimizing interference from background immunoglobulins or therapeutic antibodies. The technology aims to provide clinicians with a more practical and patient-friendly approach to precision cancer monitoring.
Strategic Roadmap: From “Local R&D” to “Global Enterprise”
Following its selection, the Marker X team will travel to Arizona in March 2026 to participate in intensive workshops led by top-tier scientists, engineers, and serial entrepreneurs. The program will provide critical guidance on U.S. FDA regulations, insurance reimbursement strategies, and international fundraising. Marker X will also gain access to de-identified clinical databases to validate the clinical utility of its technology within the U.S. healthcare system.
“Marker X is currently at a strategic turning point,” said Leo Huang, CEO of MarkerX. “Through the Mayo Clinic Accelerator, we are transitioning from a Taiwan-based R&D entity into a globally integrated enterprise. Our roadmap in Phoenix is clear: establish an ecosystem of ‘Taiwan R&D, U.S. Validation, and Global Market.” We aim to bring our leading screening and monitoring technologies to the world, significantly enhancing the quality of life for cancer patients everywhere.”
Media Contact
Debby Chen | Industry & Market Analyst, Office of the CEO
Marker X CO., LTD. (銳準生醫)